Pay in 4 interest-free payments of $6.58 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
This can lead to proptosis or bulging of the eyes, diplopia or double vision, and a significant reduction in the patient's quality of life
Retatrutide is an investigational triple receptor agonist (GLP-1, GIP, glucagon) not yet approved by the MHRA or EMA as of 2025
Prescribing decisions are made by licensed providers through OpenLoop Healthcare Partners, PC based on independent medical evaluation
Progress tracking to optimize results: Monitor your skin improvements, wound healing progress, or hair regrowth results
US$ 26.45
US$ 24.56
US$ 26.04
US$ 21.39
US$ 28.22
